MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the appointment of Michael Magee as vice president, quality and compliance..

新泽西州蒙茅斯交界处（商业新闻）——Tris Pharma，Inc.（Tris），一家专注于注意力缺陷多动障碍（ADHD），疼痛，成瘾和神经系统疾病的商业阶段生物制药公司，今天宣布任命迈克尔·马吉为质量和合规副总裁。。

“Michael joins Tris Pharma at an incredibly exciting time in which we have an established portfolio of ADHD medications and a diverse pipeline of late-stage assets, and where his proven track record in the pharmaceutical industry will play a key role in further enhancing our ongoing quality assurance and compliance initiatives,” said Ketan Mehta, founder and CEO at Tris Pharma.

Tris Pharma创始人兼首席执行官科坦·梅塔（KetanMehta）表示：“迈克尔加入Tris Pharma正值一个激动人心的时刻，我们拥有一套完善的ADHD药物组合和多样化的后期资产渠道，他在制药行业的良好业绩将在进一步加强我们正在进行的质量保证和合规举措方面发挥关键作用。”。

“With Michael on board, we are well-positioned to navigate our growth and continue delivering on our mission to optimize patient outcomes through differentiated therapeutic approaches.'.

“有了迈克尔的加入，我们就可以很好地驾驭我们的发展，并继续履行我们的使命，通过差异化的治疗方法优化患者的预后。”。

Mr. Magee will lead and further strengthen Tris Pharma’s continued development and management of quality and compliance operations via the current Good Manufacturing Practices (cGMP) Compliance function of the organization. His responsibilities will include ensuring adherence to, and compliance with, established company quality policies, practices, and standard operating procedures and federal regulations, directing the quality of materials purchased, processed, manufactured and/or distributed by the company, and overseeing and ensuring compliance with all appropriate regulatory agencies..

Magee先生将通过组织当前的良好生产规范（cGMP）合规职能，领导并进一步加强Tris Pharma对质量和合规运营的持续发展和管理。他的职责将包括确保遵守既定的公司质量政策、做法、标准操作程序和联邦法规，指导公司采购、加工、制造和/或分销的材料质量，监督并确保遵守所有适当的监管机构。。

“I am excited to join the Tris Pharma team and partner across the organization to drive transformational growth in key areas of the business and optimize outcomes for the patients that we serve,” said Mr. Magee. “My passion for motivating teams to have a strong, organization-wide common purpose and sense of community aligns closely with Tris Pharma’s values.

Magee先生说：“我很高兴加入Tris Pharma团队和整个组织的合作伙伴，推动业务关键领域的转型增长，并为我们服务的患者优化结果。”。“我对激励团队拥有强大的组织范围内的共同目标和社区意识的热情与Tris Pharma的价值观密切相关。

Along with the company’s transformative technology and differentiated products, as well as its drug development, manufacturing and commercial capabilities that Tris Pharma is expanding to reach patients globally, the opportunity to join the company was tremendous.”.

随着该公司的变革性技术和差异化产品，以及Tris Pharma正在全球范围内扩展到患者的药物开发，制造和商业能力，加入该公司的机会是巨大的。”。

Mr. Magee brings more than 25 years of experience to Tris Pharma, most recently serving as senior vice president of quality assurance at SCA Pharmaceuticals where he led the multi-site, quality assurance division for the industry leading 503B outsourcing company. Prior to SCA, Mr. Magee held varying roles of increasing responsibility at Ferring Pharmaceuticals, Windtree Therapeutics and Johnson & Johnson, supporting quality assurance, regulatory compliance, operations, technical services and more across the companies.

Magee先生为Tris Pharma带来了超过25年的经验，最近他担任SCA Pharmaceuticals的质量保证高级副总裁，领导业界领先的503B外包公司的多地点质量保证部门。在加入SCA之前，Magee先生在Ferring Pharmaceuticals、Windtree Therapeutics和Johnson＆Johnson担任了不同的角色，承担着越来越大的责任，为公司的质量保证、法规遵从性、运营、技术服务等提供支持。

Mr. Magee received his Bachelor of Science in Chemistry from Moravian University and a Bachelor of Science in Pharmacy from St. Joseph’s University (Philadelphia College of Pharmacy)..

Magee先生拥有摩拉维亚大学的化学理学学士学位和圣约瑟夫大学（费城药学院）的药学理学学士学位。。

“Michael brings a wealth of knowledge and a deep understanding of the regulatory and quality landscape, which will be instrumental in maintaining our unwavering commitment to developing therapeutics of the highest quality across ADHD, pain, addiction and neurological disorders,” said Nicholas Cappuccino, Ph.D., chief quality officer, senior vice president of quality & compliance at Tris Pharma.

首席质量官尼古拉斯·卡布奇诺（NicholasCappuccino）博士表示：“迈克尔（Michael）拥有丰富的知识，对监管和质量领域有着深刻的理解，这将有助于我们坚定不移地致力于开发针对ADHD、疼痛、成瘾和神经系统疾病的最高质量治疗方法。”，Tris Pharma质量与合规高级副总裁。

“I look forward to collaborating with Michael to further elevate our quality assurance and regulatory compliance practices.”.

“我期待着与Michael合作，进一步提高我们的质量保证和法规遵从性。”。

About Tris Pharma

关于Tris Pharma

Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain and neurological disorders, including addiction and diseases of the central nervous system. Tris is an established commercial organization with a robust portfolio of best-in-class ADHD products and a promising pipeline of differentiated, near-term drug candidates.

Tris Pharma是一家私营、创新驱动的生物制药公司，正在应用其药物开发能力和专有技术来改变ADHD、疼痛和神经系统疾病（包括成瘾和中枢神经系统疾病）的治疗方法。Tris是一家成熟的商业组织，拥有一流的ADHD产品的强大组合，以及有前途的差异化近期候选药物渠道。

More information is available at www.trispharma.com and on LinkedIn @TrisPharma..

更多信息请访问www.trispharma.com和LinkedIn@trispharma。。